Boehringer to settle blood thinner drug suits for $650m


German-based firm Boehringer-Ingelheim has committed $650 million (£390 million) to settle around 4000 US court cases relating to its anticoagulant stroke prevention drug Pradaxa (dabigatran).

The patients bringing the lawsuits claim that the drug caused serious, and even fatal, bleeding. However, the US Food and Drugs Administration has backed up Boehringer’s view on Pradaxa’s risk-benefit profile compared to Warfarin, the established standard treatment. A study of 134,000 US patients found that, although Pradaxa is associated with an increased risk of major gastrointestinal bleeding, it presents no greater risk of heart attacks, and is more effective at preventing clot-related strokes, bleeding in the brain and death.

Boehringer lawyer Andreas Neumann said in a statement that the company expects most of the plaintiffs to accept the settlement. He stated that the company was confident it should win the suits based on its evidence, but explained that ‘we have to consider that juries composed of lay people have to decide about very difficult scientific matters. This does not allow reliable predictions for the outcome of a huge number of individual trials. This settlement allows our company to avoid the distraction and uncertainty of protracted litigation.’


Related Content

Chemistry World podcast - June 2013

3 June 2013 Podcast | Monthly

news image

We discover 300 years of chemistry in Edinburgh with Eleanor Campbell, and explore the secrets of the main group elements

Business roundup

28 July 2011 Business

news image

Industry news, August 2011

Most Read

Computational tool leaves electrides with nowhere to hide

25 February 2015 Research

news image

Electride criteria pave way for new research into these fascinating materials

The mothers of invention

24 February 2015 Managing Change

news image

Nina Notman profiles four researchers successfully balancing an academic career with family life

Most Commented

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Nanoporous methane storage – an impossible target?

18 February 2015 Research

news image

Identifying performance limits for nanoporous materials highlights that current methane storage goals might be unrealistic